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Case Report: Tocilizumab for the
Treatment of SARS-CoV-2 Infection
in a Patient With Aplastic Anemia
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and Adam F. Binder 1
1 Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States, 2Department of Medicine,
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While cytokine storm develops in a minority of patients with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are
desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor
antibody, has been utilized for the treatment of cytokine storm in a number of severe
inflammatory conditions, including in patients with severe coronavirus disease 2019
(COVID-19). Here, we present the first published case utilizing this therapy in a patient
with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine
storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and
elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm
resolved, and the patient was ultimately safely discharged from the hospital.
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INTRODUCTION
To date, the novel SARS-CoV-2 has infected more than 4,500,000 people in the United States
and more than three times that number worldwide. While a minority of patients develop severe
symptoms from COVID-19 requiring hospitalization, treatment options for those who do are
limited. There is no currently accepted standard and new approaches are desperately needed.
Following the initial reports of COVID-19 from Wuhan, China, Huang et al. (1) described the
clinical features of the disease. The subset of patients who required intensive care was found to
have significant increase in inflammatory cytokines (1). Others have since shown that an increase
in interleukin (IL)-6 is associated with critical illness (2) and mortality (3) in COVID-19 patients.
Treatment with tocilizumab, an anti-IL-6 receptor (IL-6R) antibody, has been proposed as a
strategy to control cytokine storm associated with COVID-19 (4, 5). This strategy has been utilized
by others in the treatment of cytokine storm associated with SARS-CoV-2 (6–9). We describe
here the first reported use of tocilizumab in a patient with underlying immune dysregulation,
specifically aplastic anemia (AA). In our patient with underlying immunodeficiency, tocilizumab
successfully reversed cytokine storm due to COVID-19 and the patient was successfully discharged
from the hospital.
CASE DESCRIPTION
A 72-year-old man with a past medical history of AA, amegakaryocytic thrombocytopenia and
chronic kidney disease (CKD) stage 3 presented in April 2020 with high fever, cough, and
progressive fatigue.
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Aplastic anemia had been diagnosed in 2014 and initially
responded to therapy with horse anti-thymocyte globulin
(ATG), methylprednisolone and cyclosporine A. Nine months
later, his disease progressed and he was treated with rabbit
ATG, methylprednisolone, and cyclosporine A. In late 2019,
his disease progressed primarily as thrombocytopenia due
to acquired amegakaryocytic thrombocytopenia (AAT). He
received four doses of rituximab in early 2020 for treatment
of AAT without response. Bone marrow biopsy performed 2
months prior to presentation was hypocellular with 15–20%
bilineage hematopoiesis and near absence of megakaryocytes
without evidence of dysplasia or increased blasts. While his
diagnosis is most accurately classified as AAT at the time
of presentation, he had been consistently pancytopenic for 4
months despite treatment with cyclosporine A and remained
dependent on platelet transfusions. Family and psycho-social
history were non-contributory.
Physical examination at the time of presentation was notable
for fever of 103.7F and mild tachycardia (HR 104) with
normal oxygen saturation (97%) without supplemental oxygen.
He appeared in mild respiratory distress, but pulmonary
examination was unremarkable. His initial laboratory studies
were notable for severe lymphopenia, which was different from
his baseline pancytopenia and elevated C-reactive protein (CRP)
and IL-6 as noted in Table 1. Chest radiograph revealed a
consolidation in the left midlung, possibly representative of
pneumonia (Figure 1A).
The patient was treated empirically with hydroxychloroquine
(400mg twice a day for 1 day, followed by 200mg twice
a day for 4 days) for possible COVID-19 in the setting of
immunosuppression. Ceftriaxone and azithromycin were added
TABLE 1 | Notable laboratory studies at baseline and throughout hospitalization.
Normal range Baseline Day−30 Admission Day 0 Day 5 Day 9 Tocilizumab Day 11 Day 12 Day 14 Day 21 Day 28 Discharge Day 31
WBC 4.0–11.0 × 109 cells/L 2.5 2.6 0.4 0.7 0.5 0.3 0.4 0.1 0.5 0.5
ANC 1.6–8.0 × 109 cells/L 1.5 2.36 3.00 5.00 0.460 0.220 0.360 – 0.210 0.220
ALC 0.8–4.8 × 109 cells/L 0.800 0.080 0.070 0.130 0.030 0.050 0.030 – 0.220 0.170
Hb (g/dL) 14.0–17.0 g/dL 9.2 8.1 6.1 8.2 6.8 8.0 8.3 7.4 7.0 6.6
Platelet 140–400 × 109 cells/L 24 10 20 24 9 14 10 19 24 18
Creatinine 0.7–1.4 mg/dL 2.34 2.59 2.1 2.34 3.04 2.7 1.91 2.00 1.31 1.6
D-dimer < 230 ng/mL NR 673 1,005 1,781 1,833 2,209 997 1,932 1,010 960
PT 9.4–13.0 s – 12.4 – 16.5 – – – 16.1 17.0 13.5
aPTT 25–36 s – 29 – 32 – – – 28 28 29
LDH 125–240 IU/L 267 206 232 296 – 272 209 180 142 122
Ferritin 30–400 ng/mL NR – 4,122 7,535 7,291 11,363
(Day 13)
6,339 2,541 2,326 2,533
CRP <0.80 mg/dL NR 5.10 18.70 34.70 40.10 32.60 8.20 7.20 2.80 1.4
IL-6 <5.00 pg/mL NR 58.96 – – – – – – 1223.8 –
SARS-
CoV-2
PCR
Negative NR Positive Positive Negative
(Day 17)
Positive
(Day 29)
WBC, white blood cell count; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; Hb, hemoglobin; PT, prothrombin time; aPTT, activated partial thromboplastin time;
LDH, lactate dehydrogenase; CRP, C-reactive protein; NR, not reported.
for possible community acquired pneumonia. On admission day
0, SARS-CoV-2 PCR nasal swab came back positive. For the
first several days of the hospitalization, the patient had persistent
fever (range 100–104F) and intermittently required oxygen up
to 2 L/min via nasal cannula to maintain oxygen saturation
above 94%.
By hospital day 5, he had developed progressive pancytopenia
and required near daily transfusion of packed red blood
cells and platelets. Due to persistent high fever, and now
neutropenia, antibacterial coverage was broadened to cefepime,
then meropenem, and antifungal prophylaxis with posaconazole
was added. Hewas also started on tbo-filgrastim and eltrombopag
for management of severe neutropenia and thrombocytopenia.
On hospital day 9, the patient developed lethargy and hypoxia
requiring supplemental oxygen of 6 L/min via nasal cannula and
subsequently Venturi mask at 50% FiO2. Repeat chest radiograph
demonstrated significant worsening with bilateral pulmonary
infiltrates (Figure 1B). Inflammatory markers, including ferritin
and CRP were significantly increased and acute on chronic renal
failure worsened (Table 1).
The clinical picture was consistent with cytokine storm due to
severe COVID-19 and the patient promptly received tocilizumab
5 mg/kg (400mg) on hospital day 11. The patient received
a single dose of methylprednisolone 60mg IV immediately
prior to tocilizumab administration but did not otherwise
receive corticosteroid treatment during his admission. The
same day, the patient’s fever resolved and he developed mild
hypothermia (minimum 94.6F). Over the next several days, his
temperature normalized, oxygen requirements steadily declined,
inflammatory markers decreased and acute renal failure resolved.
The patient remained pancytopenic and transfusion dependent.
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FIGURE 1 | Select chest radiograph images during the patient’s hospitalization.
Meropenem was discontinued and he was transitioned to oral
levofloxacin prophylaxis due to persistent neutropenia.
On hospital day 18, the patient developed mild recurrent fever
(100.5F, repeat 100.9F). The following day, his fever increased
significantly to 103.9F and his oxygen requirement increased to
10 L/min. Chest radiograph revealed new pulmonary infiltrates
(Figure 1C). Cefepime was resumed and vancomycin and
therapeutic voriconazole were added. Despite these efforts, the
patient developed mild hypotension (BP 90/40) which resolved
with fluid resuscitation. Antibiotics were further broadened to
meropenem and the patient received a single dose of tobramycin.
Inflammatory markers at this time were relatively stable.
By hospital day 20, the patient had again clinically improved.
His blood pressure remained within normal range and his oxygen
requirement decreased to 6 L/min by nasal cannula. The exact
cause of his brief clinical deterioration was unclear but was
presumed to be due to a secondary bacterial pneumonia. Over
the subsequent days, he completed a 7-day course of meropenem
and vancomycin. He remained afebrile on this treatment and his
oxygen requirement slowly normalized. His repeat IL-6 level on
day 28 was significantly elevated at 1223.8 pg/mL.
The patient was discharged home on hospital day 31. He
remained pancytopenic and transfusion dependent at the time
of hospital discharge. Notably, his SARS-CoV-2 PCR testing
has remained persistently positive as of hospital day 29 (with
the exception of a single negative result on day 17, which was
thought to be a false negative). It is unclear whether detectable
viral RNA represents persistent infectiousness or whether non-
infectious RNA fragments are being detected. Twenty two days
after hospital discharge, SARS-CoV-2 PCR was repeated and
was negative.
DISCUSSION
Hyperinflammatory syndromes, such as the cytokine storm
observed in patients with severe SARS-CoV-2 infection, play
a major role in the development of critical illness associated
with viral infections. Multiple reports have identified significant
increases in inflammatory markers, including IL-6, in patients
with severe SARS-CoV-2 infection (1, 3, 10–12). In one
retrospective analysis, elevated ferritin (mean 1297.6 vs.
614.0 ng/mL), CRP (mean 34.1 vs. 126.6 mg/L), and IL-6 levels
(mean 6.8 vs. 11.4 pg/mL) have been identified as risk factors for
mortality (3). Significant elevation in IL-6 has previously been
identified as a significant factor in the development of cytokine
release syndrome (CRS) in patients undergoing chimeric antigen
receptor T cell (CAR-T) therapy, as well (13).
IL-6 serves many important immunologic and hematopoietic
functions, including differentiation of activated B cells to
immunoglobulin-producing plasma cells, differentiation of naïve
CD4+ T cells to Th17 cells and of CD8+ T cells to cytotoxic
T cells, promotion of T follicular helper cell differentiation,
inhibition of regulatory T cell (Treg) differentiation and
stimulation of acute-phase proteins (14). In combination
with erythropoietin and IL-3, IL-6 promotes formation
of myeloid, erythroid, megakaryocyte, and macrophage
colonies (15). Tocilizumab is a recombinant, humanized
monoclonal antibody which binds and inhibits the soluble
IL-6 receptor and has been utilized in the treatment of auto-
inflammatory conditions (16) and CRS following CAR-T
therapy (17). Based on the success of treating CAR-T-
associated CRS with anti-IL-6 therapy, the same strategy
has been proposed for the treatment of cytokine storm
associated with severe SARS-CoV-2 infection (4, 5). Many
case reports and case series support the use of tocilizumab
in this setting (6–9) and multiple clinical trials investigating
this treatment are underway in the United States and abroad
(NCT04317092, NCT04331795, NCT04335071, NCT04356937,
and others).
The most promising data thus far are from a retrospective
analysis of the use of 1–2 doses of tocilizumab in 21 adult patients
with severe or critical COVID-19 treated at two centers in China.
Following treatment, all patients became afebrile and 70% had
decreased oxygen requirements. Nineteen patients (90.5%) had
been discharged from the hospital, including two critical patients,
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after a mean of 13.5 days following treatment with tocilizumab.
No patients developed recurrent fever or symptoms of recurrent
pneumonia (9).
A retrospective analysis of 30 French patients age < 80 years
with severe COVID-19 treated with tocilizumab after at least 5
prior days of illness requiring at least 6 L/min of oxygen therapy
who developed rapidly deteriorating COVID-19 pneumonia
(increase by more than 3 L/min oxygen therapy in 12 h) showed
that treatment with tocilizumab 8 mg/kg for 1–2 doses was
associated with decreased ICU admission (OR 0.17, 95% CI 0.06–
0.48, p = 0.001) and mechanical ventilation (OR 0.42, 95% CI
0.20–0.89, p = 0.025) compared to matched controls. No benefit
in mortality was seen after weighted analysis (18).
The clinical response observed in our AA patient following
treatment with tocilizumab is in line with previously published
reports despite his underlying immunodeficiency. After a single
dose of tocilizumab, his clinical and laboratory markers of severe
COVID-19 had improved.While he did experience a brief clinical
deterioration 7–8 days following tocilizumab administration, this
was thought to be due to secondary bacterial pneumonia as
evidenced by the pattern change in the chest radiologic image,
and unlikely related to use of tocilizumab.
Both the development of cytokine storm and the resolution
thereof following tocilizumab is particularly notable in our
patient in light of his underlying immune dysfunction.
Activation of aberrant T cells and monocytes, which produce
large numbers of inflammatory cytokines, appears to be a
driving factor and has been implicated in many patients with
severe COVID-19 (9, 11, 19). Guo et al. (20) profiled the
peripheral immune cells of two severe SARS-CoV-2-infected
patients at three time points (severe stage: 12 h, recovery
stage: 5 days and healthy stage: 7 days) following treatment
with tocilizumab to better understand the immune effects
of this intervention. Notably, a subpopulation of monocytes
was only present in the severe stage while other distinct
subpopulations were present at recovery and healthy stages.
Gene expression of TNF, IL10, CCL3, and IL6 were significantly
higher in the severe stage-specific monocytes, suggesting that
a specific monocyte subpopulation may contribute to the
inflammatory storm seen in patients with severe COVID-
19. Additionally, interaction of IL-6/IL-6R ligand/receptor
pairs were attenuated by tocilizumab treatment. Following
treatment with tocilizumab, expression of genes involved in
the acute inflammatory response and leukocyte chemotaxis
were significantly decreased. B cells and effector CD8+ T cells
and proliferative CD8+ T cells were significantly increased
compared to controls, suggesting that anti-virus humoral
and cell-mediated immune responses remained intact despite
tocilizumab therapy. There was no difference in CD4+ T
cells, naïve CD8+ T cells and B cells in patients vs. healthy
controls (20).
IL-6 level was not available immediately following tocilizumab
administration in our patient due to laboratory error, however,
our patient’s IL-6 level was found to be significantly elevated
∼2 weeks after tocilizumab administration despite clinical
improvement. This trend is consistent with what has been
previously reported following tocilizumab treatment in patients
with rheumatoid arthritis and Castleman disease. In these
patients, significant rise in IL-6 level following tocilizumab
treatment has been observed. IL-6 level peaked at day 14
after therapy remained at stable elevation until day 42
(21). This phenomenon has been suggested to be due to
binding of tocilizumab to IL-6R leading to delayed clearance
and accumulation of IL-6 in the blood (21, 22). That this
elevation persists at a stable level weeks after tocilizumab
administration has been suggested to be due to continued IL-
6 production at approximately the same rate as direct IL-6
degredation (21).
The totality of immune effects of SARS-CoV-2 infection and
tocilizumab therapy remain to be fully understood, as does the
impact of treatment with tocilizumab on the clinical course in
patients with AA. It is known that IL-6 impacts the balance of
Th17 and Treg cells by promoting proliferation of the former
and inhibiting the later (14) and that imbalance in Th17/Treg
cells is an important feature in the development of AA (23).
Additionally, elevation in IL-6 has been observed in children
with AA compared to healthy controls (193.48 vs. 4.58 pg/mL,
p < 0.001). The degree of IL-6 elevation was associated with
severity of disease and reduction in IL-6 level was associated
with response to immunosuppressive therapy (IST) (24). Others
have found that children with higher baseline IL-6 elevation
are more likely to respond to IST (211.89 vs. 18.09 pg/mL,
p= 0.005) and that an IL-6 level of at least 36.8 pg/mL had
81% sensitivity to distinguish responders from non-responders
(25). There are currently no published data regarding use of
tocilizumab for treatment of AA, although data on the role
of IL-6 in dysregulation of Th17/Treg balance and the role
of this imbalance in the development of AA suggests that
tocilizumab may play a role. It remains to be seen whether
our patient will benefit in his blood cell counts following
tocilizumab therapy.
Being a single patient report is amajor limitation. However, we
felt that it’s prudent to report the first use of tocilizumab to treat
a cytokine storm induced severe SARSCoV-2 in a patient with
underlying immunodeficiency. The findings are consistent with
what has been reported in immune competent patients. The rapid
clinical improvement and decline of all inflammatory markers
suggests that tocilizumab was effective in reversing COVID-19-
associated cytokine storm.
PATIENT PERSPECTIVE
“I started feeling tired and had no energy even to walk short
distances. I had a fever and minor cough. I went to the
Emergency Room [sic] at Jefferson [sic], and I tested positive
[for SARS-CoV-2] and they admitted me. The first couple of
weeks (I was in the hospital for a total of 4 weeks), I slept
most of the time. I was either on my back in bed or in a
chair. After I started to get better, I was more awake and I
became depressed and bored. I looked forward to my daily
[physical therapy] visits. It is certainly difficult not having
visitors. The doctors and nurses were excellent. The doctors
communicated with my wife every day. I simply cannot say
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enough about the care I received. When released from the
hospital, I came directly home and have been receiving nursing
care and [physical therapy].
My case is complicated by the fact that prior to my
hospitalization I required transfusions for aplastic anemia.
The medical staff worked diligently to have a procedure for
transfusing patients with [COVID-19] as outpatients. They were
able to have a procedure set up of which I was the first. The care
and attention I received at the infusion center was well-organized
and excellent. My improvement is progressing and I am getting
better every day.”
CONCLUSION
Until now, treatment of severe COVID-19 with tocilizumab
has been tried in patients without pre-existing immune
dysfunction. We have reported the first use of this treatment
strategy in a patient with underlying immunodeficiency.
It is notable that both the symptoms and signs of severe
COVID-19 and the result of therapy with tocilizumab is
similar to prior reports in patients with presumably normal
baseline immune function. More work is desperately
needed to better understand the immunological impacts of
severe SARS-CoV-2 infection and the risks and benefits of
tocilizumab treatment.
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